Virological surveillance and antiviral resistance of human influenza virus in Argentina, 2005-2008

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 30, Issue 6, 2011, Pages 634-640

  Pontoriero, Andrea ^a   Baumeister, Elsa ^a   Campos, Ana M ^a   Savy, Vilma L ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

Author keywords

Antiviral agents; Argentina; Drug resistance, viral; Influenza A virus; Influenza, human

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ANTIMICROBIAL ACTIVITY; DISEASE CONTROL; DISEASE PREVALENCE; DISEASE SPREAD; DRUG RESISTANCE; GENOMICS; HEALTH RISK; INFLUENZA; INHIBITION; MUTATION; PUBLIC HEALTH; SPATIOTEMPORAL ANALYSIS;

ANIMAL; ANTIVIRAL RESISTANCE; ARGENTINA; ARTICLE; CELL LINE; DOG; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEALTH SURVEY; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MORBIDITY; MULTIDRUG RESISTANCE; POINT MUTATION; SEASON; VIROLOGY; VIRUS CULTURE;

AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; ARGENTINA; CELL LINE; DOGS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MORBIDITY; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; POINT MUTATION; POPULATION SURVEILLANCE; SEASONS; VIRUS CULTIVATION; ZANAMIVIR;

ARGENTINA;

CERCOPITHECINE HERPESVIRUS 1; HUMAN INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZA B VIRUS;

EID: 84859959373     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892011001200023     Document Type: Article

References (28)

1. Molinari A, Ortega-Sanchez I, Messonnier ML, Thompson WW, WortleyPM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-96. (Pubitemid 46879994)
2. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine. 2002;20(25-26):3068-87.
3. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2008-2009 influenza season. Wkly Epidemiol Rec. 2008;83(9):81-7.
4. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season. Wkly Epidemiol Rec. 2008;83(41):366-72.
5. Davies WL, Grunert RR, Haff RF, McGahen JW, Neumayer EM, Paulshock M, et al. Antiviral activity of 1-adamantanamine (amantadine).Science. 1964;144:862-3.
6. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol. 1992;3:21-30.
7. von Itzstein M, Wu WY, Kok GB, Pegg MS,Dyason JC, Jin B, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363(6428): 418-23. (Pubitemid 23179386)
8. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366(9492):1175- 81. (Pubitemid 41393595)
9. Pontoriero A, Baumeister E, Campos AM, Moreno A, Cadario ME, SavyV. Surveillance of adamantane resistance among influenza A H3 virusesisolated in Argentina between 2001 and 2007. Rev Argent Microbiol. 2008;40(3):180-4.
10. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, Schweiger B, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis. 2009;15(4):552-60. Available from: http://www.nimr.mrc.ac.uk/ documents/about/interim-report-feb-2009.pdf Accessed 15 September 2011.
11. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site:design, synthesis and structuralanalysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997;119:681-90. (Pubitemid 27101232)
12. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, etal. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008;13(5). Available from: http://www.eurosurveillance. org/images/dynamic/EE/V13N05/art8026.pdf Accessed 5 February 2009.
13. Hay A, Daniels R, Lin Y, Zheng X, Gregory V, Hou T, et al. World Influenza Centre interim report, February 2009. London: WHO Influenza Centre; 2009. Available from: http://www.nimr.mrc.ac.uk/documents/about/interim-report- feb-2009.pdf Accessed 15 September 2011.
14. WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241548090-eng.pdf Accessed 16 September 2011.
15. Lackenby A, Democratis J, Siqueira MM, Zambon MC. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir Ther. 2008;13(6):809-20.
16. Jonges M, van der Lubben IM, Dijkstra F, Verhoef L, Koopmans M, Meijer A. Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008. Antiviral Res. 2009;83(3):290-7.
17. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2007;44(2):197-202. (Pubitemid 46079980)
18. Kawai N, Ikematsu H, Iwaki N, Kawashima T, Maeda T, Mitsuoka S,et al. Longer virus shedding in influenza B than in influenza A amongoutpatients treated with oseltamivir. J Infect. 2007;55(3):267-72. (Pubitemid 47248483)
19. World Health Organization. Influenza A (H1N1) viruses resistant to oseltamivir-last quarter 2007 to 5 May 2008. Geneva: WHO; 2008. Available from: http://www.who.int/influenza/patient-care/antivirals/oseltamivir-summary/en/ Accessed 13 November 2011.
20. Hay A, Daniels R, Lin Y, Zheng X, Gregory V, Bennett M, et al. Characteristics of human influenza AH1N1, AH3N2 and B viruses isolatedSeptember 2007 to February 2008. London: WHO Influenza Centre; 2008. Available from: http://www.nimr.mrc.ac.uk/wic/report/documents/interin-report-mar-2008. pdf Accessed 26 September 2008.
21. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47(7):2264-72. (Pubitemid 36753582)
22. Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 2004;103(1-2):195-7. (Pubitemid 38649079)
23. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA,et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52(9):3284-92.
24. Lackenby A, Baldevarona J, Democratis J, Wigmore H, Andrews N, Ellis J, et al. Decreasing sensitivity of influenza B viruses to neuraminidase inhibitors. In: Katz JM, ed. Options for the control of influenza IV. London: International Medical Press Ltd.; 2008. P. 238.
25. Cané A, Casanueva E, Iolster T, Sticco N, Richards L, Sosa P, etal. First isolation of a oseltamivir-resistant influenza A (H1N1) strain in Argentina. Pediatr Infect Dis J. 2010;29(4):384.
26. Valinotto LE, Diez RA, Barrero PR, Farías JA, López EL, Mistchenko AS. Emergenceof intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus. Antivir Ther. 2010;15(6):923-7.
27. World Health Organization. Weekly update on oseltamivir resistance to influenza H1N1 (2009) viruses. Geneva: WHO; 2009. Available from: http://www.who.int/csr/disease/influenza/2011-01-12-weekly-web-update- oseltamivir-resistance.pdf Accessed 14 January 2011.
28. Meijer A, Jonges M, Abbink F, Ang W, van Beek J, Beersma M, et al. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res. 2011;92(1):81-9.